Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 76 of 116

  1. UC-GIG-2411

    Ningbo Cancer Hospital

    Metastatic or locally advanced irresectable (stage IV) gastric cancer (GC) or esophagogastric junction cancer (EGJC), with and without actionable biomarker (HER2/Claudin18.2)

    phase 2 small molecule active

    1 trial

  2. UC-GMP-2504

    Ningbo Cancer Hospital

    Adult patients with advanced hormone receptor positive (HR+), HER2- breast cancer after at least a first line of endocrine therapy combined with CDK4/6 inhibitor in the metastatic setting

    phase 2 small molecule active

    1 trial

  3. UC-IMM-2302

    Ningbo Cancer Hospital

    Patients with dMMR/MSI (non-colorectal/non-endometrial) locally advanced or metastatic cancer

    phase 2 small molecule active

    1 trial

  4. UC-IMM-2509/2510

    Ningbo Cancer Hospital

    NEOREM: Localized solid malignancies that are eligible to receive neo-adjuvant therapy and have medical unmet needs related to disease-free survival, overall survival or quality of life / NEO-1: Resectable stage III cutaneous or mucosal melanoma amenable to intratumoral neo-adjuvant immunotherapy.

    phase 2 small molecule active

    1 trial

  5. UC-IMM-2511/2512

    Ningbo Cancer Hospital

    METAREM:Patients with advanced cancer, as defined as unresectable locally advanced malignancies or metastatic cancers (including leukemias and lymphomas). META-1: Patients in first-line therapy for advanced metastatic NSCLC with PD-L1 Tumor Proportion Score (TPS) >50%, without EGFR/ ALK/ ROS1 mutations and irrespective of their histological subtype (squamous or non-squamous)

    phase 2 small molecule active

    1 trial

  6. UC-SAR-2212_L-UteCIN

    Ningbo Cancer Hospital

    Localized, resected, FIGO stage I (2018 classification), uterine leiomyosarcoma

    phase 2 small molecule active

    1 trial

  7. UC_0160/1406

    Ningbo Cancer Hospital

    Penis carcinoma

    phase 2 small molecule active

    1 trial

  8. UID 4270

    Istituto Gentili S.r.l.

    Metastatic hormone receptor-positive/HER2-negative breast cancer

    phase 2 small molecule active

    1 trial

  9. UKD-IKF-Double-T

    The George Institute

    relapsed/refractory Large B-Cell Lymphoma

    phase 2 small molecule active

    1 trial

  10. UKT-IKF-DEPECA-1

    The George Institute

    locally advanced or metastatic penile squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  11. US-guided RFA

    The First People's Hospital of Lianyungang

    Liver Cancer

    phase 2 other active

    1 trial

  12. US-guided laser ablation for refractory neoplasms

    The First People's Hospital of Lianyungang

    Refractory Neoplasms

    phase 2 other active

    1 trial

  13. Ubamatamab

    Regeneron UK Limited

    Advanced/Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  14. Ubamatamab

    Regeneron UK Limited

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  15. Ubamatamab

    Regeneron UK Limited

    Recurrent Ovarian Cancer

    phase 2 small molecule active

    1 trial

  16. Ublituximab

    TG THERAPEUTICS, INC.

    Non-Hodgkins Lymphoma

    phase 2 small molecule completed

    2 trials

  17. Ublituximab

    TG THERAPEUTICS, INC.

    Follicular Lymphoma

    phase 2 small molecule terminated

    1 trial

  18. Umbralisib

    TG THERAPEUTICS, INC.

    Lymphoma

    phase 2 small molecule terminated

    1 trial

  19. Umbralisib

    TG THERAPEUTICS, INC.

    Marginal Zone Lymphoma

    phase 2 small molecule completed

    1 trial

  20. Umbralisib

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 2 small molecule completed

    4 trials

  21. Utidelone

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer

    phase 2 small molecule active

    1 trial

  22. V940-005

    Merck Sharp and Dohme

    Muscle-invasive Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  23. V940-012

    Merck Sharp and Dohme

    Melanoma

    phase 2 small molecule active

    1 trial

  24. V940-013

    Merck Sharp and Dohme

    Non-small cell lung cancer stage IV

    phase 2 small molecule active

    1 trial

  25. VACl

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia, Adult

    phase 2 small molecule active

    1 trial

  26. VATS

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 other active

    1 trial

  27. VCAR33

    Vor Biopharma

    Leukemia, Myeloid, Acute

    phase 2 mab terminated

    1 trial

  28. VEGF inhibitor PTC299

    PTC THERAPEUTICS, INC.

    Kaposi's Sarcoma

    phase 2 small molecule terminated

    1 trial

  29. VEN (Venetoclax)

    The First People's Hospital of Lianyungang

    Adult T-cell Leukemia/Lymphoma

    phase 2 small molecule active

    1 trial

  30. VEN (Venetoclax)

    The First People's Hospital of Lianyungang

    Myelodysplastic Neoplasms

    phase 2 small molecule active

    1 trial

  31. VESANOID 10 mg, capsule molle

    The George Institute

    Oligometastatic solid cancer

    phase 2 small molecule active

    1 trial

  32. VESPA

    Fondazione Telethon ETS

    Metastatic pancreatic ductal adenocarcinoma (mPDAC)

    phase 2 small molecule active

    1 trial

  33. VGX-3100

    INOVIO PHARMACEUTICALS, INC.

    Anal Neoplasm

    phase 2 mab completed

    1 trial

  34. VHIO19001

    The George Institute

    Resectable Gastric cancer (GC) or Gastroesophageal Junction cancer (GEJC)

    phase 2 small molecule active

    1 trial

  35. VHIO23001

    The George Institute

    Metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  36. VHIO23002

    The George Institute

    Advanced selected solid tumors: melanoma, non-small cell lung cancer (NSCLC) and cervical cancer.

    phase 2 small molecule active

    1 trial

  37. VHIO24002

    The George Institute

    Patients with localized renal cell carcinoma

    phase 2 small molecule active

    1 trial

  38. VINORELBINE for Hodgkin’s lymphoma

    Fondazione Telethon ETS

    Hodgkin’s lymphoma

    phase 2 small molecule active

    1 trial

  39. VIR-5818

    Vir Biotechnology

    Locally Advanced or Metastatic HER2-Expressing Cancers

    phase 2 small molecule active

    1 trial

  40. VK-2019

    Cullinan Therapeutics

    Nasopharyngeal Carcinoma

    phase 2 small molecule terminated

    1 trial

  41. VOR33

    Vor Biopharma

    Leukemia, Myeloid, Acute

    phase 2 mab terminated

    1 trial

  42. VS-6766, VS-6063

    Vera Therapeutics

    Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

    phase 2 small molecule active

    1 trial

  43. VV1

    Regeneron UK Limited

    Melanoma

    phase 2 mab active

    1 trial

  44. VX15/2503 + avelumab

    VACCINEX, INC.

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule completed

    1 trial

  45. Vaccine

    Atrium Therapeutics

    Pediatric Cancer

    phase 2 mab active

    1 trial

  46. Valemetostat Tosylate, Valemetostat Tosylate

    The George Institute

    Adult patients with histologically/cytologically confirmed progressive metastatic or recurrent solid tumor, who have selected chromatin remodeling deficiency in at least one of the following genes: SMARCB1, SMARCA4, SMARCA2, SMARCC1, SMARCC2, ARID1A, ARID1B, PBRM1, BAP1and other SWI/SNF sub-units; or molecularly (Wildtype) and phenotypically-selected Clear cell endometrial or ovarian carcinoma cancers.

    phase 2 small molecule active

    1 trial

  47. Valemetostat Tosylate, Valemetostat Tosylate

    Daiichi Sankyo

    Relapsed/Refractory Peripheral T-Cell Lymphoma

    phase 2 small molecule active

    1 trial

  48. Vebreltinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Potentially Resectable MET-altered Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.